NO984524L - Amfipatiske molekyler som kolesterol- og andre lipoidopptaksinhibitorer - Google Patents

Amfipatiske molekyler som kolesterol- og andre lipoidopptaksinhibitorer

Info

Publication number
NO984524L
NO984524L NO984524A NO984524A NO984524L NO 984524 L NO984524 L NO 984524L NO 984524 A NO984524 A NO 984524A NO 984524 A NO984524 A NO 984524A NO 984524 L NO984524 L NO 984524L
Authority
NO
Norway
Prior art keywords
cholesterol
amphipathic
molecules
uptake inhibitors
amphipathic molecules
Prior art date
Application number
NO984524A
Other languages
English (en)
Other versions
NO984524D0 (no
Inventor
Dario Boffelli
Helmut Hauser
Original Assignee
Dario Boffelli
Helmut Hauser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606686.5A external-priority patent/GB9606686D0/en
Priority claimed from GBGB9626920.4A external-priority patent/GB9626920D0/en
Application filed by Dario Boffelli, Helmut Hauser filed Critical Dario Boffelli
Publication of NO984524D0 publication Critical patent/NO984524D0/no
Publication of NO984524L publication Critical patent/NO984524L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Kolesterolbiosyntesen kan inhiberes med egnede inhibitorer, f.eks. statinene. Imidlertid kan hyper- kolesterolemi, enten den er familiær eller diettindusert, og mer generelt hyperlipidemi, ikke behandles adekvat med kolesterolbiosynteseinhibitorer alene, siden kroppens kolesterol erverves både ved opptak fra dietten og ved endogen syntese. Lipid tas også opp fra tarmen. Dette problem tilnærmes ved tilveiebringelse av ett eller flere molekyler med amfipatiske områder for inhibering av opptaket av kolesterol og andre lipider fra tarmen. Fedme kan også behandles eller forebygges på denne måte, likeså aterosklerose. Eksempler på egnede molekyler med amfi- patiske områder omfatter naturlige og variant apoproteiner og andre proteiner og peptider med en amfipatisk a-heliks som består av minst tilnærmet 15 amino- syrer.
NO984524A 1996-03-29 1998-09-28 Amfipatiske molekyler som kolesterol- og andre lipoidopptaksinhibitorer NO984524L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9606686.5A GB9606686D0 (en) 1996-03-29 1996-03-29 Medical use
GBGB9626920.4A GB9626920D0 (en) 1996-12-24 1996-12-24 Medical use
PCT/IB1997/000379 WO1997036927A1 (en) 1996-03-29 1997-03-27 Amphipathic molecules as cholesterol and other lipid uptake inhibitors

Publications (2)

Publication Number Publication Date
NO984524D0 NO984524D0 (no) 1998-09-28
NO984524L true NO984524L (no) 1998-11-30

Family

ID=26309021

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984524A NO984524L (no) 1996-03-29 1998-09-28 Amfipatiske molekyler som kolesterol- og andre lipoidopptaksinhibitorer

Country Status (9)

Country Link
US (1) US20010005714A1 (no)
EP (1) EP0889906A1 (no)
JP (1) JP2000509020A (no)
CN (1) CN1109047C (no)
AU (1) AU710061B2 (no)
CA (1) CA2249459A1 (no)
NO (1) NO984524L (no)
NZ (1) NZ331980A (no)
WO (1) WO1997036927A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
EP1090634A1 (en) * 1999-10-01 2001-04-11 Helmut Hauser Agents for reducing cholesterol and lipid uptake
US7250304B2 (en) 2000-03-31 2007-07-31 The Regents Of The University Of California Functional assay of high-density lipoprotein
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
AU2007237157B2 (en) * 2000-08-24 2009-04-09 The Regents Of The University Of California Peptides that ameliorate atherosclerosis
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
KR100771322B1 (ko) * 2000-11-28 2007-10-29 미쯔비시 웰 파마 가부시키가이샤 항비만제 및 건강식품
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
JP2006507223A (ja) 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
CA2514303C (en) * 2002-11-13 2012-09-18 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
DE10343815A1 (de) * 2003-09-22 2005-04-14 B.R.A.H.M.S Ag Verfahren zur Diagnose von Erkrankungen unter Bestimmung von Apolipoprotein C-I, und dessen Verwendung in der Therapie von Erkrankungen
WO2006034056A2 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
EP1827472A4 (en) 2004-12-06 2012-09-05 Univ California METHOD FOR IMPROVING THE STRUCTURE AND FUNCTION OF ARTERIOLS
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP2269623A1 (en) * 2005-04-29 2011-01-05 The Regents of The University of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
ZA200807356B (en) * 2006-03-24 2009-12-30 Unilever Plc Healthy food product
EP1836906B1 (en) * 2006-03-24 2009-07-01 Unilever N.V. Healthy food product
WO2007110296A1 (en) * 2006-03-24 2007-10-04 Unilever N.V. Healthy food product
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
EP2682400B1 (en) 2007-08-28 2017-09-20 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007930A1 (en) * 1993-09-15 1995-03-23 Cv Therapeutics, Inc. Protein for mediating cholesterol absorption and an inhibitor thereof
US5373009A (en) * 1994-02-02 1994-12-13 American Home Products Corporation Dibenzofuranyl esters of N-heterocyclic carboxylic acids

Also Published As

Publication number Publication date
CN1109047C (zh) 2003-05-21
AU710061B2 (en) 1999-09-09
WO1997036927A1 (en) 1997-10-09
CN1216995A (zh) 1999-05-19
US20010005714A1 (en) 2001-06-28
JP2000509020A (ja) 2000-07-18
AU2174197A (en) 1997-10-22
EP0889906A1 (en) 1999-01-13
NO984524D0 (no) 1998-09-28
NZ331980A (en) 2000-09-29
CA2249459A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
NO984524L (no) Amfipatiske molekyler som kolesterol- og andre lipoidopptaksinhibitorer
Kalluri et al. Reactive oxygen species expose cryptic epitopes associated with autoimmune Goodpasture syndrome
PH12013500208A1 (en) Tolerogenic peptides from myelin basic priotein
NO20092860L (no) 2, 6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
EP0526544A4 (en) Therapeutic uses of actin-binding compounds
Pusztai Studies in immunochemistry. 18. The isolation and properties of a sialomucopolysaccharide possessing blood-group Le-a specificity and virus-receptor activity.
MX9801159A (es) Metodos de reduccion o para mantener los niveles reducidos de lipidos en la sangre usando composiciones de proteina ob.
Hayashibara et al. Binding of the amino-terminal region of myosin alkali 1 light chain to actin and its effect on actin-myosin interaction
DE69632546D1 (de) Ob proteinderivate mit verlängerter halbwertzeit
Larsson et al. A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity
Omori-Satoh et al. The antihemorrhagic factor, erinacin, from the European hedgehog (Erinaceus europaeus), a metalloprotease inhibitor of large molecular size possessing ficolin/opsonin P35 lectin domains
RU94042935A (ru) Водорастворенные комплексы включения соединений бензотиофена с водорастворимыми циклодекстринами, способ их получения и фармацевтический состав
DK0506748T3 (da) Aminosyrer, peptider eller derivater deraf bundet til fedtstoffer
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
Zou et al. Structural changes and evolution of peptides during chill storage of pork
ES549115A0 (es) Procedimiento de producir preparaciones para tratar pacien- tes de hemofilia a inhibidores
HK1048819A1 (en) Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
EP0716591A4 (en) METHODS AND COMPOSITIONS FOR FIXING TAU AND MAP2c PROTEINS
Buelt et al. Modification of the adipocyte lipid binding protein by sulfhydryl reagents and analysis of the fatty acid binding domain
Vogel et al. Phosphorus-31 nuclear magnetic resonance studies of the two phosphoserine residues of hen egg white ovalbumin
AU4152799A (en) Glycoproteins having lipid mobilising properties and therapeutic applications thereof
Akamatsu et al. Quantitative analyses of the structure‐hydrophobicity relationship for N‐acetyl di‐and tripeptide amides
DK0683791T3 (da) Vandig proteinsammensætning, glycoprotein indeholdt deri, fremgangsmåde til opnåelse deraf og anvendelser deraf
Robert et al. [48] Structural glycoproteins
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application